From Research findings to Therapeutic opportunity:
The study presented here suggests that Bergapten (5-methoxypsoralen), by increasing the expression of its target genes, it may: (i) decrease the expression of Dihydropyrimidine dehydrogenase (DPYD); (ii) increase 5-FU accumulation in cancer cells; (iii) augment and restore chemosensitivity in drug-resistant Human cancers; (iv) promote anti-tumor effect; and (v) enhance the efficacy of anticancer drug treatment.
Thereby, it may inhibit proliferation, chemoresistance and apoptosis of cancer cells. Thus, pharmacological formulations encompassing “Bergapten (5-methoxypsoralen) or its analogue either alone or in combination with 5-FU, or any other anticancer drugs” may be used to inhibit cancer progression (Figs. 1-3).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Undisclosed information: How Bergapten (5-methoxypsoralen) decreases the expression of Dihydropyrimidine dehydrogenase (DPYD)?
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at email@example.com
Citation: Boominathan, L., Natural product-derived combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: Bergapten (5-methoxypsoralen), a natural psoralen derivative present in many fruits and vegetables, decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 4/January/2017, 10.01 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org